| Literature DB >> 17967467 |
Daniela Galimberti1, Diego Scalabrini, Chiara Fenoglio, Milena De Riz, Cristoforo Comi, Eliana Venturelli, Francesca Cortini, Mirko Piola, Maurizio Leone, Umberto Dianzani, Sandra D'Alfonso, Francesco Monaco, Nereo Bresolin, Elio Scarpini.
Abstract
Macrophage-derived chemokine (MDC/CCL22) plays a role in Experimental Autoimmune Encephalomyelitis (EAE), the animal model of Multiple Sclerosis (MS). MDC/CCL22 gene is part of a chemokine cluster, which includes also thymus and Activation-Regulated Chemokine (TARC/CCL17). The frequency of the C/T and C/A Single Nucleotide Polymorphisms (SNPs) in the promoter and coding sequence of CCL22 as well as the C/T SNP in the promoter of CCL17 were determined in 370 patients with Multiple Sclerosis (MS) compared with 380 controls. A trend towards a decreased allelic frequency of the A allele of the CCL22 C/A SNP as well as of the T allele of the CCL17 C/T SNP was found in patients compared with controls. The frequency of the AT haplotype was significantly decreased in MS patients (P=0.017, OR: 0.49, CI: 0.28-0.87). Stratifying patients according to gender, the observed association was even more pronounced in male patients compared with male controls (P=0.004, OR=0.18, 95% CI: 0.06-0.50), whereas no significant differences were observed in females. Therefore, the presence of the AT haplotype in chromosome 16 chemokine cluster is likely to confer a decreased risk of developing MS, particularly in males.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17967467 DOI： 10.1016/j.jns.2007.10.001
Source DB: PubMed Journal: J Neurol Sci ISSN： 0022-510X Impact factor: 3.181